A Phase 2 interventional study of Placebo and Istaroxime in Acute Decompensated Heart Failure, sponsored by Windtree Therapeutics. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-24.
Sponsored by Windtree Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 375 studies in Heart Failure with a site in China, this one is the 128th largest by enrollment of the 246 interventional ones that give a count, is one of 11 that started in 2015, is one of 22 in phase 2, and was the 60th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
375 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 29
First in 1983; this study’s year is marked. 11 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 127 across the 246 interventional studies, 540 across the 129 observational. Of the 115 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 375 have an industry lead sponsor. The 10 most frequent:
Windtree Therapeutics is the lead sponsor of 14 studies on the registry; none are open to participants now.
Windtree Therapeutics has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
46 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 46 to your calendar (.ics) → With an account.
Among the 375 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle. The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused via i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.
To assess the safety, tolerability and efficacy of two different doses of istaroxime (0.5 and 1.0 µg/kg/min) in comparison with placebo, including cardiovascular and renal tolerability, as well as changes in biological markers such as N-terminal prohormone brain natriuretic peptide (NT-proBNP) and troponin T (cTnT). The study will be conducted in 96 Chinese and Italian patients with Acute Decompensated Heart Failure. This is a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Patients were randomly assigned to one of two doses of istaroxime or placebo in a 2:1 ratio within two sequential cohorts of 60 patients each. This 31-day study includes a screening period (Days -1), a treatment period (Day 1), a post-treatment period (Days 2-4), and a follow-up period (which includes one patient visit on Day 30).
In all the Italian patients and in a subset of Chinese patients pharmacokinetics and metabolism of istaroxime shall also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who fulfill the following inclusion criteria at screening will be considered for the study:
Exclusion Criteria:
Any of the following criteria established at screening would render a patient ineligible for the study:
The following laboratory exclusion criteria, verified based on results obtained within the last 24 hours of hospitalization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV infusion of placebo for 24 hours
Drug: Placebo
The istaroxime treatment dosed at 0.5 µg/kg/min via IV infusion for 24 hours
Drug: Istaroxime
The istaroxime treatment dosed at 1.0 µg/kg/min via IV infusion for 24 hours
Drug: Istaroxime
IV of matching saline solution
IV infusion of 0.5 µg/kg/min or 1.0 µg/kg/min istaroxime
Change in E/Ea Ratio
Change from baseline at 24 hours in the unitless ratio of E (cm/sec) to Ea (or e') (cm/sec) as measured by echocardiogram. The endpoint is the Tissue Doppler echocardiography showing measurement of mitral E/Ea ratio for assessment of diastolic dysfunction. Initially mitral E wave is measured. After that, color Tissue Doppler (tissue velocity imaging or TVI) mode is switched on to assess tissue Doppler. The cursor is placed over the medial mitral annulus and tissue Doppler tracing obtained. This allows Ea velocity to be measured. Higher values are suggestive of a worse outcome; less than 8 is normal.
Time frame: 24 hours
Change in LVEF
Change from baseline at 24 hours in LV ejection fraction (LVEF) by tissue Doppler
Time frame: 24 hours
Change in SVI
Change from baseline at 24 hours in stroke volume index (SVI) by tissue Doppler
Time frame: 24 hours
Change in E/A Ratio
Change from baseline at 24 hours in E/A ratio by tissue Doppler
Time frame: 24 hours
Change in LV End Systolic Volume
Change from baseline in left ventricular end systolic volume (LVESV) by tissue Doppler
Time frame: 24 hours
Change in LV End Diastolic Volume
Change from baseline in left ventricular end diastolic volume (LVEDV) by tissue Doppler
Time frame: 24 hours
Change in Dyspnea
Measured using a visual analog scale (0 to 100). Higher scores indicate less dyspnea.
Time frame: 24 hours
Change in cTnT
Safety endpoint: Changes in troponin (cTnT)
Time frame: 24 hours
Change in eGFR
Safety endpoint: Change from baseline in estimated glomerular filtration rate (eGFR)
Time frame: 24 Hours
Participants With Clinically or Hemodynamically Significant Episodes of Arrhythmias
Safety endpoint: Number of participants with incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous ECG dynamic monitoring
Time frame: 24 hours
PR Interval
Safety Endpoint: The PR interval, measured in milliseconds, extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex (the onset of ventricular depolarization).
Time frame: 24 Hours
QRS Duration
Safety endpoint: The quasi-random signal (QRS) duration represents the time for ventricular depolarization, normally 0.06 to 0.10 seconds.
Time frame: 24 hours
QTc Interval
Safety Endpoint: The corrected QT interval (QTc) on an ECG represents the duration in milliseconds of the ventricular action potential, which physiologically correlates with the duration of the ventricular depolarization and repolarization.
Time frame: 24 Hours
All-Cause Mortality at Day 30
Safety endpoint: Mortality at Day 30
Time frame: 30 days
RBC - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in red blood cells (RBC)
Time frame: Day 3
Hematocrit - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hematocrit
Time frame: Day 3
Hemoglobin - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hemoglobin
Time frame: Day 3
White Blood Cells (WBC) - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in WBC
Time frame: Day 3
Platelets - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in platelets
Time frame: Day 3
Potassium - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in potassium
Time frame: Day 3
Sodium - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in sodium
Time frame: Day 3
Calcium - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in calcium
Time frame: Day 3
BUN - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in blood urea nitrogen (BUN)
Time frame: Day 3
ALT - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in alanine aminotransferase (ALT)
Time frame: Day 3
AST - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in aspartate aminotransferase (AST)
Time frame: Day 3
Total Bilirubin - Shift
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in total bilirubin
Time frame: Day 3
| Milestone | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Started | 39 | 41 | 40 |
| Completed | 35 | 39 | 33 |
| Not completed | 4 | 2 | 7 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 | 5 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 2 |
Change from baseline at 24 hours in the unitless ratio of E (cm/sec) to Ea (or e') (cm/sec) as measured by echocardiogram. The endpoint is the Tissue Doppler echocardiography showing measurement of mitral E/Ea ratio for assessment of diastolic dysfunction. Initially mitral E wave is measured. After that, color Tissue Doppler (tissue velocity imaging or TVI) mode is switched on to assess tissue Doppler. The cursor is placed over the medial mitral annulus and tissue Doppler tracing obtained. This allows Ea velocity to be measured. Higher values are suggestive of a worse outcome; less than 8 is normal.
| Unitless ratio | Istaroxime 0.5 µg/kg/Min | Placebo Cohort I | Istaroxime 1.0 µg/kg/Min | Placebo Cohort II |
|---|---|---|---|---|
| Change in E/Ea Ratio | -4.55 (-6.05 to -3.04) | -1.55 (-3.77 to 0.67) | -3.16 (-4.09 to -2.24) | -1.08 (-2.30 to 0.13) |
Change from baseline at 24 hours in LV ejection fraction (LVEF) by tissue Doppler
| % of blood leaving the heart | Istaroxime 0.5 µg/kg/Min | Placebo Cohort I | Istaroxime 1.0 µg/kg/Min | Placebo Cohort II |
|---|---|---|---|---|
| Change in LVEF | 3.026 (1.850 to 4.203) | 1.263 (-0.401 to 2.927) | 3.818 (2.362 to 5.275) | 2.833 (0.861 to 4.805) |
Change from baseline at 24 hours in stroke volume index (SVI) by tissue Doppler
| mL/m² | Istaroxime 0.5 µg/kg/Min | Placebo Cohort I | Istaroxime 1.0 µg/kg/Min | Placebo Cohort II |
|---|---|---|---|---|
| Change in SVI | 5.334 (3.371 to 7.296) | 1.649 (-1.126 to 4.425) | 5.488 (3.882 to 7.094) | 3.178 (1.030 to 5.327) |
Change from baseline at 24 hours in E/A ratio by tissue Doppler
| Unitless ratio | Istaroxime 0.5 µg/kg/Min | Placebo Cohort I | Istaroxime 1.0 µg/kg/Min | Placebo Cohort II |
|---|---|---|---|---|
| Change in E/A Ratio | -0.643 (-1.091 to -0.197) | 0.133 (-0.463 to 0.729) | -0.654 (-1.093 to -0.216) | 0.175 (-0.419 to 0.769) |
Change from baseline in left ventricular end systolic volume (LVESV) by tissue Doppler
| mL | Istaroxime 0.5 µg/kg/Min | Placebo Cohort I | Istaroxime 1.0 µg/kg/Min | Placebo Cohort II |
|---|---|---|---|---|
| Change in LV End Systolic Volume | -7.105 (-10.933 to -3.277) | -1.736 (-7.150 to 3.677) | -11.39 (-17.438 to -5.350) | -11.83 (-20.017 to -3.649) |
Change from baseline in left ventricular end diastolic volume (LVEDV) by tissue Doppler
| mL | Istaroxime 0.5 µg/kg/Min | Placebo Cohort I | Istaroxime 1.0 µg/kg/Min | Placebo Cohort II |
|---|---|---|---|---|
| Change in LV End Diastolic Volume | -0.710 (-4.243 to 2.822) | 0.947 (-4.049 to 5.944) | -3.666 (-9.507 to 2.173) | -7.611 (-15.518 to 0.296) |
Measured using a visual analog scale (0 to 100). Higher scores indicate less dyspnea.
| Score on a scale (Visual Analog Scale) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Change in Dyspnea | 9.75 ± 11.80 | 9.14 ± 10.08 | 12.09 ± 14.79 |
Safety endpoint: Changes in troponin (cTnT)
| ng/L | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Change in cTnT | 0.23 ± 10.83 | 0.51 ± 7.58 | -4.06 ± 49.97 |
Safety endpoint: Change from baseline in estimated glomerular filtration rate (eGFR)
| ml/min/1.73·m² | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Change in eGFR | -0.60 ± 14.71 | 5.19 ± 16.25 | 7.65 ± 13.22 |
Safety endpoint: Number of participants with incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous ECG dynamic monitoring
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Participants With Clinically or Hemodynamically Significant Episodes of Arrhythmias | 6 | 1 | 4 |
Safety Endpoint: The PR interval, measured in milliseconds, extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex (the onset of ventricular depolarization).
| msec | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| PR Interval | 184.0 ± 31.27 | 179.2 ± 28.11 | 169.41 ± 32.72 |
Safety endpoint: The quasi-random signal (QRS) duration represents the time for ventricular depolarization, normally 0.06 to 0.10 seconds.
| msec | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| QRS Duration | 125.2 ± 37.11 | 132.5 ± 31.59 | 127.6 ± 26.65 |
Safety Endpoint: The corrected QT interval (QTc) on an ECG represents the duration in milliseconds of the ventricular action potential, which physiologically correlates with the duration of the ventricular depolarization and repolarization.
| msec | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| QTc Interval | 472.8 ± 41.90 | 480.8 ± 55.72 | 486.9 ± 40.18 |
Safety endpoint: Mortality at Day 30
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| All-Cause Mortality at Day 30 | 0 | 0 | 2 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in red blood cells (RBC)
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 22 | 17 | 21 |
| Normal to Abnormal | 5 | 3 | 4 |
| Abnormal to Normal | 2 | 3 | 4 |
| Abnormal to Abnormal | 8 | 16 | 7 |
| Missing | 2 | 2 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hematocrit
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 21 | 15 | 17 |
| Normal to Abnormal | 7 | 3 | 5 |
| Abnormal to Normal | 3 | 7 | 6 |
| Abnormal to Abnormal | 6 | 14 | 8 |
| Missing | 2 | 2 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hemoglobin
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 23 | 13 | 23 |
| Normal to Abnormal | 5 | 3 | 2 |
| Abnormal to Normal | 1 | 7 | 5 |
| Abnormal to Abnormal | 8 | 16 | 6 |
| Missing | 2 | 2 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in WBC
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 35 | 30 | 25 |
| Normal to Abnormal | 2 | 6 | 6 |
| Abnormal to Normal | 0 | 1 | 2 |
| Abnormal to Abnormal | 0 | 2 | 3 |
| Missing | 2 | 2 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in platelets
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 26 | 32 | 31 |
| Normal to Abnormal | 3 | 2 | 4 |
| Abnormal to Normal | 4 | 1 | 0 |
| Abnormal to Abnormal | 4 | 3 | 1 |
| Missing | 2 | 3 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in potassium
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 37 | 40 | 34 |
| Normal to Abnormal | 1 | 0 | 2 |
| Abnormal to Normal | 0 | 0 | 0 |
| Abnormal to Abnormal | 0 | 0 | 0 |
| Missing | 1 | 1 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in sodium
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 23 | 21 | 19 |
| Normal to Abnormal | 9 | 12 | 8 |
| Abnormal to Normal | 4 | 2 | 1 |
| Abnormal to Abnormal | 2 | 5 | 8 |
| Missing | 1 | 1 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in calcium
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 24 | 26 | 20 |
| Normal to Abnormal | 4 | 2 | 1 |
| Abnormal to Normal | 3 | 2 | 9 |
| Abnormal to Abnormal | 3 | 1 | 4 |
| Missing | 5 | 10 | 6 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in blood urea nitrogen (BUN)
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 11 | 13 | 14 |
| Normal to Abnormal | 7 | 4 | 6 |
| Abnormal to Normal | 3 | 2 | 8 |
| Abnormal to Abnormal | 14 | 16 | 7 |
| Missing | 4 | 6 | 5 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in alanine aminotransferase (ALT)
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 29 | 31 | 29 |
| Normal to Abnormal | 1 | 1 | 2 |
| Abnormal to Normal | 2 | 1 | 0 |
| Abnormal to Abnormal | 4 | 5 | 5 |
| Missing | 3 | 3 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in aspartate aminotransferase (AST)
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 28 | 28 | 24 |
| Normal to Abnormal | 1 | 4 | 5 |
| Abnormal to Normal | 3 | 1 | 4 |
| Abnormal to Abnormal | 4 | 4 | 3 |
| Missing | 3 | 4 | 4 |
Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in total bilirubin
| Participants | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Normal to Normal | 9 | 21 | 13 |
| Normal to Abnormal | 3 | 2 | 2 |
| Abnormal to Normal | 9 | 3 | 6 |
| Abnormal to Abnormal | 13 | 11 | 15 |
| Missing | 5 | 4 | 4 |
Collected over Enrollment to 30 days after enrollment. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/39 (0%) | 2/39 (5.1%) | 23/39 (59%) |
| Istaroxime 0.5 µg/kg/Min | 0/41 (0%) | 2/41 (4.9%) | 31/41 (75.6%) |
| Istaroxime 1.0 µg/kg/Min | 2/40 (5%) | 6/40 (15%) | 33/40 (82.5%) |
| Event | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Cardiac failureCardiac disorders | 1/39 | 2/41 | 2/40 |
| Transient ischaemic attackNervous system disorders | 1/39 | 0/41 | 0/40 |
| HyperventilationRespiratory, thoracic and mediastinal disorders | 1/39 | 0/41 | 0/40 |
| HypotensionVascular disorders | 1/39 | 0/41 | 0/40 |
| Cardiac failure congestiveCardiac disorders | 0/39 | 0/41 | 1/40 |
| Cardiogenic shockCardiac disorders | 0/39 | 0/41 | 1/40 |
| Cardiac deathGeneral disorders | 0/39 | 0/41 | 1/40 |
| Renal embolismRenal and urinary disorders | 0/39 | 0/41 | 1/40 |
| Event | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min |
|---|---|---|---|
| Infusion site painGeneral disorders | 0/39 | 17/41 | 12/40 |
| VomitingGastrointestinal disorders | 1/39 | 1/41 | 10/40 |
| NauseaGastrointestinal disorders | 0/39 | 3/41 | 9/40 |
| HypotensionVascular disorders | 6/39 | 3/41 | 1/40 |
| DizzinessNervous system disorders | 0/39 | 1/41 | 5/40 |
| PhlebitisVascular disorders | 0/39 | 5/41 | 2/40 |
| Upper respiratory tract infectionInfections and infestations | 0/39 | 3/41 | 4/40 |
| Atrial fibrillationCardiac disorders | 0/39 | 4/41 | 0/40 |
| Blood bilirubin increasedInvestigations | 2/39 | 4/41 | 0/40 |
| Cardiac failureCardiac disorders | 3/39 | 0/41 | 0/40 |
Intent-to-Treat
| Age, Continuous(years) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| Mean | 56.67 ± 16.21 | 59.73 ± 15.53 | 52.23 ± 13.02 | 56.24 ± 14.98 |
| Sex: Female, Male(Participants) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| Female | 5 | 7 | 6 | 18 |
| Male | 34 | 34 | 34 | 102 |
| Race (NIH/OMB)(Participants) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 32 | 24 | 40 | 96 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 7 | 17 | 0 | 24 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| China | 32 | 24 | 40 | 96 |
| Italy | 7 | 17 | 0 | 24 |
| E/Ea Ratio(Unitless ratio) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| Mean | 17.0 ± 5.33 | 20.4 ± 7.87 | 15.1 ± 5.48 | 17.5 ± 6.36 |
| Left ventricular ejection fraction (LVEF)(% of blood in heart pumped) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| Mean | 26.2 ± 7.4 | 27.4 ± 6.7 | 28.7 ± 7.2 | 27.4 ± 7.1 |
| Stroke Volume Index(ml/m²) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| Mean | 21.6 ± 7.73 | 25.9 ± 7.10 | 17.1 ± 5.69 | 21.6 ± 6.89 |
| Dyspnea(Scores on a scale) | Placebo | Istaroxime 0.5 µg/kg/Min | Istaroxime 1.0 µg/kg/Min | Total |
|---|---|---|---|---|
| Mean | 70.8 ± 21.32 | 73.6 ± 19.49 | 71.5 ± 20.95 | 72.0 ± 20.59 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Dec 2015, a primary completion of Aug 2018 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.
Results were first posted in May 2023, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Istaroxime
Windtree Therapeutics